

Testing for Coccidioidomycosis among Community-Acquired Pneumonia Patients, Southern California, USA¹

Sara Y. Tartof,² Kaitlin Benedict,² Fagen Xie, Gunter K. Rieg, Calvin C. Yu, Richard Contreras, Jonathan Truong, Kimberlee Fong, Hung Fu Tseng, Steven J. Jacobsen, Rajal K. Mody

We conducted a cohort study to identify characteristics associated with testing for, and testing positive for, coccidioidomycosis among patients with community-acquired pneumonia in southern California, USA. Limited and delayed testing probably leads to underdiagnosis among non-Hispanic black, Filipino, or Hispanic patients and among high-risk groups, including persons in whom antimicrobial drug therapy has failed.

The public health impact of coccidioidomycosis (Valley fever) in the United States is increasing. The causative fungus, *Coccidioides*, is endemic to the southwestern and western United States. In 2015, California reported 3,015 cases, ≈25% of all US cases (1,2). In areas of Arizona where coccidioidomycosis is highly endemic, the disease might be responsible for 15%–29% of community-acquired pneumonia (CAP) cases; however, in some studies, <15% of CAP patients are tested, suggesting that the disease is underrecognized, even in endemic areas (3–5). Testing practices for CAP patients in southern California have not been well documented. Therefore, we determined the proportion of CAP patients who were tested, the proportion who tested positive, and clinical factors associated with being tested and having confirmed coccidioidomycosis among patients enrolled in the Kaiser Permanente Southern California (KPSC) healthcare system in 2011.

The Study

KPSC is an integrated healthcare organization with ≈4.4 million members who are representative of the socioeconomic and racial/ethnic diversity of the area's population (6). KPSC uses electronic health records (EHRs) to

Author affiliations: Kaiser Permanente Southern California, Pasadena, California, USA (S.Y. Tartof, F. Xie, R. Contreras, H.F. Tseng, S.J. Jacobsen); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (K. Benedict, R.K. Mody); Southern California Permanente Medical Group, Pasadena (G.K. Rieg, K.C. Yu, J. Truong, K. Fong)

DOI: <https://doi.org/10.3201/eid2404.161568>

integrate medical information from all care and laboratory settings. We included all KPSC patients meeting membership criteria who had CAP diagnosed and received treatment for CAP as outpatients (online Technical Appendix Table 1, <https://wwwnc.cdc.gov/EID/article/24/4/16-1658-Techapp1.pdf>). Information about each patient's medical history during 2001–2011 was based on International Classification of Disease, Ninth Revision (ICD-9), codes retrieved from EHRs.

We searched CAP patient EHRs to identify coccidioidomycosis laboratory testing from all care settings (online Technical Appendix Table 1). We sought documentation of a coccidioidomycosis-related ICD-9 code (114.X) in any encounter type from 1 week before to 1 year after the sample collection date for patients with confirmed coccidioidomycosis cases. We excluded patients having received an ICD-9 coccidioidomycosis diagnosis before 2011 and those who had a hospitalization during the 2 weeks before CAP diagnosis.

To identify factors for multivariable modeling, we used χ^2 and *t*-tests (statistical significance defined as $p < 0.2$), clinical knowledge, and a backward selection algorithm testing for interaction terms. We conducted analyses in SAS version 9.3 (SAS Institute, Cary, NC, USA).

After exclusions, the final cohort consisted of 33,756 patients (online Technical Appendix Table 2). Among patients with CAP, 2,061 (6%) were tested for coccidioidomycosis within 1 year of CAP diagnosis. A median of 6 (mean 46) days and a median of 2 (mean 5) clinic encounters elapsed between the index CAP date (i.e., the date the CAP ICD-9 code was first used) and the first order for a coccidioidomycosis test. Among patients who initially tested negative, 5% had a repeat test within 30 days and 8% within 90 days.

In adjusted analyses, testing for coccidioidomycosis was less likely among female patients and among Hispanic patients who survived 1 year after the index CAP date (compared with surviving non-Hispanic whites) (online Technical Appendix Table 2). Pulmonary clinics were most likely to test for coccidioidomycosis. Increasing

¹Preliminary results from this study were presented at the 60th Annual Coccidioidomycosis Study Group Meeting; Sacramento, California, USA; April 9, 2016.

²These authors contributed equally to this article.

numbers of healthcare encounters involving a CAP ICD-9 code, inpatient visits, chest radiograph orders, and antimicrobial drug prescriptions in the year after CAP diagnosis increased the odds of being tested for coccidioidomycosis. Patients whose race/ethnicity was Filipino, Hispanic, American Indian/Alaska Native multiple, other, or unknown who died (from any cause) had increased odds of being tested for coccidioidomycosis compared with surviving non-Hispanic whites.

Of the 2,061 CAP patients tested for coccidioidomycosis, 377 (18%) were positive by any test; of these, 45 (12%) had ≥ 1 previous negative test before testing positive, and 172 (46%) were confirmed by complement fixation or immunodiffusion. Among those who tested positive by both IgG and IgM enzyme immunoassay (EIA), 88% were confirmed by complement fixation or immunodiffusion; only 10% of IgG-positive results and 7% of IgM-positive results were confirmed (online Technical Appendix Table 3).

In adjusted analyses, female sex was associated with reduced odds of testing positive (adjusted odds ratio [aOR] 0.60 [95% CI 0.42–0.86]). Persons of Filipino ethnicity (aOR 3.56 [95% CI 1.57–8.08]), non-Hispanic black race (aOR 2.78 [95% CI 1.50–5.12]), and Hispanic ethnicity (aOR 1.83 [95% CI 1.23–2.73]) were more likely to test positive than were non-Hispanic whites. Kern County residents were more likely to test positive than Los Angeles County residents (aOR 2.48 [95% CI 1.56–3.95]) (online Technical Appendix Table 4). Having antimicrobial drugs prescribed ≥ 2 times (in addition to the treatment-defining CAP diagnosis) from 1 week before the first CAP visit to the first coccidioidomycosis test (aOR 4.57 [95% CI 1.29–16.12]) and having chest radiographs within 1 year after CAP diagnosis (aOR 2.30 [95% CI 1.54–3.45]) were associated with increased odds of testing positive.

Conclusions

We assessed testing practices for coccidioidomycosis among patients with CAP in southern California and found that only 6% of CAP patients were tested, of whom 18% were coccidioidomycosis-positive by any test and 8% by confirmatory testing. Further, our data highlight delayed testing for some patients, low rates of retesting, and opportunities to reduce unnecessary antibiotic use.

In addition to low overall testing rates, we detected substantial testing delays, suggested by much higher estimated mean (compared with median) time to testing. We might underestimate delays because patients might have had CAP-related visits before the study period began. Delays in testing have been noted previously but were shorter among persons who knew about the disease before seeking healthcare, suggesting a benefit of community awareness (7).

Delays in testing affect healthcare use. CAP patients tested for coccidioidomycosis were more likely to have

received multiple courses of antimicrobial drugs, experienced more inpatient admissions for CAP, and received more chest radiographs than CAP patients who were not tested, suggesting substantial resource utilization and possible worsening of symptoms before coccidioidomycosis was considered. Further, patients with confirmed coccidioidomycosis were more likely to have received ≥ 2 additional antimicrobial drug prescriptions between CAP diagnosis and their first coccidioidomycosis test. Other studies have described high rates of initial and subsequent antimicrobial treatment among coccidioidomycosis patients in Arizona (5,7).

Patients of Filipino, Hispanic, non-Hispanic black, and American Indian/Alaska Native or multiple, other, or unknown race/ethnicity who died had ≈ 8 , 2, 2, and 3 times the odds of being tested for coccidioidomycosis, respectively, compared with surviving non-Hispanic whites. Although we could only capture all-cause mortality, the high probability for testing among patients who do not survive suggests possible progression of severe disease before consideration of coccidioidomycosis. Additionally, non-Hispanic black and Filipino patients with CAP had greater odds than non-Hispanic whites for having coccidioidomycosis. Historically, non-Hispanic black and Filipino patients have been identified as having increased risk for severe or disseminated coccidioidomycosis compared with other racial/ethnic groups (8–11). Unfortunately, we were unable to control for exposure-related factors, such as occupation, which might correlate with race/ethnicity.

Experts at the University of Arizona suggest that patients who initially have a negative serologic test should be retested within 2 months because serologic tests can be negative early in the course of infection (12). In our cohort, 12% of patients with any positive coccidioidomycosis test had previous negative tests. However, few CAP patients (8%) who tested negative were retested. Thus, increased awareness of repeat testing for those with persistent symptoms might be warranted. However, EIA testing has limitations; although it is widely used because it is faster and requires less technical expertise than complement fixation or immunodiffusion, the specificity is low. Having a positive EIA test result for IgG or IgM alone in our study correlated very poorly with positive confirmatory testing.

In conclusion, limited testing for coccidioidomycosis likely precludes accurate assessment of the overall frequency of the disease among CAP patients. Physician and community education might improve overall detection and result in earlier detection, which could be beneficial in decreasing overuse of antimicrobial drugs, reducing time and resources spent seeking other diagnoses, and improving monitoring for coccidioidomycosis complications.

Acknowledgments

We acknowledge Sekai Chideya-Chihota and Benjamin J. Park for early contributions to study design, Nicole Higashiyama for medical chart data support, Demosthenes Pappagianis for subject matter expertise on diagnostic methods, Lei Qian for statistical consulting, and Brendan Jackson and Tom Chiller for review and edits of the manuscript.

S.Y.T. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. F.X. and R.C. conducted and are responsible for data analyses. R.K.M. and K.B. contributed to the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

About the Author

Dr. Tartof is a research scientist at the Kaiser Permanente Southern California Department of Research and Evaluation. Her primary interests are in infectious disease epidemiology, with particular interest in antimicrobial resistance, antimicrobial stewardship, vaccine studies, hepatitis C infection, and hospital infections.

References

- Marsden-Haug N, Goldoft M, Ralston C, Limaye AP, Chua J, Hill H, et al. Coccidioidomycosis acquired in Washington State. *Clin Infect Dis*. 2013;56:847–50. <http://dx.doi.org/10.1093/cid/cis1028>
- CDC. Notice to readers: final 2015 reports of nationally notifiable infectious diseases and conditions. *MMWR Morb Mortal Wkly Rep*. 2016;65:1306–21. <http://dx.doi.org/10.15585/mmwr.mm6546a9>
- Chang DC, Anderson S, Wannemuehler K, Engelthaler DM, Erhart L, Sunenshine RH, et al. Testing for coccidioidomycosis among patients with community-acquired pneumonia. *Emerg Infect Dis*. 2008;14:1053–9. <http://dx.doi.org/10.3201/eid1407.070832>
- Kim MM, Blair JE, Carey EJ, Wu Q, Smilack JD. Coccidioid pneumonia, Phoenix, Arizona, USA, 2000–2004. *Emerg Infect Dis*. 2009;15:397–401. <http://dx.doi.org/10.3201/eid1563.081007>
- Valdivia L, Nix D, Wright M, Lindberg E, Fagan T, Lieberman D, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. *Emerg Infect Dis*. 2006;12:958–62. <http://dx.doi.org/10.3201/eid1206.060028>
- Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. *Perm J*. 2012;16:37–41. <http://dx.doi.org/10.7812/TPP/12-031>
- Tsang CA, Anderson SM, Imholte SB, Erhart LM, Chen S, Park BJ, et al. Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007–2008. *Emerg Infect Dis*. 2010;16:1738–44. <http://dx.doi.org/10.3201/eid1611.100475>
- Crum NF, Lederman ER, Stafford CM, Parrish JS, Wallace MR. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. *Medicine (Baltimore)*. 2004;83:149–75. <http://dx.doi.org/10.1097/01.md.0000126762.91040.fd>
- Rosenstein NE, Emery KW, Werner SB, Kao A, Johnson R, Rogers D, et al. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995–1996. *Clin Infect Dis*. 2001;32:708–15. <http://dx.doi.org/10.1086/319203>
- Smith CE, Beard RR, Whiting EG, Rosenberger HG. Varieties of coccidioid infection in relation to the epidemiology and control of the diseases. *Am J Public Health Nations Health*. 1946;36:1394–402. <http://dx.doi.org/10.2105/AJPH.36.12.1394>
- Gifford M. Coccidioidomycosis, Kern County [cited 2016 Jul 12]. <http://kerncountyvalleyfever.com/wp-content/uploads/2013/04/LibraryCocci-Article-1939.pdf>
- Valley Fever Center for Excellence. Valley fever (coccidioidomycosis) tutorial for primary care professionals [cited 2016 Jul 12]. http://vfce.arizona.edu/sites/vfce/files/tutorial_for_primary_care_professionals.pdf

Address for correspondence: Sara Y. Tartof, Kaiser Permanente Southern California, Department of Research and Evaluation, 100 S Los Robles, 2nd Fl, Pasadena, CA, 91101, USA; email: sara.y.tartof@kp.org

EID Adds Advanced Search Features for Articles

Emerging Infectious Diseases now has an advanced search feature that makes it easier to find articles by using keywords, names of authors, and specified date ranges. You can sort and refine search results by manuscript number, volume or issue number, or article type. A quick start guide and expandable help section show you how to optimize your searches.

<https://wwwnc.cdc.gov/eid/AdvancedSearch>

EID's new mapping feature allows you to search for articles from specific countries by using a map or table to locate countries. You can refine search results by article type, volume and issue, and date, and bookmark your search results.

<https://wwwnc.cdc.gov/eid/ArticleMap>



Testing for Coccidioidomycosis among Community-Acquired Pneumonia Patients, Southern California, USA

Technical Appendix

Technical Appendix Table 1. Case Definitions and Criteria for Inclusion and Exclusion for Conditions of Interest

Condition	Case Definition	Details
Community-Acquired Pneumonia	<ol style="list-style-type: none"> 1) Select International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) diagnosis codes 2) Chest radiograph (identified by Current Procedural Terminology [CPT] code) within 2 weeks before to 4 weeks after the date the CAP ICD-9 code was first used 3) Prescription for a systemic antibacterial antibiotic within 2 weeks before to 2 weeks after the date the CAP ICD-9 code was first used 	<ul style="list-style-type: none"> • 480.9 (viral pneumonia, unspecified) • 482.9 (bacterial pneumonia, unspecified) • 485 (bronchopneumonia, organism unspecified) • 486 (pneumonia, organism unspecified) <p>CPT code: 71010, 71020, 71021, 71022, 71035, 71101, or 71111</p>
Community-Acquired Pneumonia Exclusion Criteria	Those with a hospitalization in the 2 weeks before CAP diagnosis (to minimize hospital-acquired infections) were excluded	
Community-Acquired Pneumonia Membership Criteria	Those KPSC patients with continuous enrollment for one year before their CAP diagnosis date (allowing a 31-d gap for administrative delays in membership renewal) were included	
Coccidioidomycosis	Positive test by enzyme immunoassay (EIA) for IgM or IgG, complement fixation (CF), or immunodiffusion (ID) from any source in the 1 y following the date the CAP ICD-9 code was first used	
Confirmed Coccidioidomycosis	Positive CF or ID test, or culture of <i>Coccidioides</i> or histological report identifying <i>Coccidioides</i> among patients with antibody testing.	
Coccidioidomycosis Exclusion Criteria	Patients with a coccidioidomycosis diagnosis (based on ICD-9 code 114.X) before 2011 were excluded	

Technical Appendix Table 2. Comparison of Characteristics of Patients Tested for Coccidioidomycosis and those not Tested among Patients Presenting with Community-Acquired Pneumonia (CAP) in 2011

Characteristic	Total CAP Patients	Patients Not-tested for Coccidioidomycosis* Total n = 31,695 (100%)	Patients Tested for Coccidioidomycosis* Total n = 2,061 (100%)	Odds Ratio	95% CI	Adjusted Odds Ratio [†]	95% CI
Sex							
Female	17,086	16,094 (50.8%)	992 (48.1%)	0.90	0.82–0.98	0.85	0.77–0.95
Male	16,670	15,601 (49.2%)	1,069 (51.9%)	1.00	Ref.	1.000	Ref.
Age Group							
≤9 y	9,643	9,513 (30.0%)	130 (6.3%)	1.00	Ref.	1.00	Ref.
10–18 y	3,357	3,254 (10.3%)	103 (5.0%)	2.32	1.78–3.01	3.08	2.32–4.09
19–40 y	3,533	3,254 (10.3%)	279 (13.5%)	6.27	5.09–7.78	7.81	5.56–10.96
41–60 y	7,194	6,494 (20.5%)	700 (34.0%)	7.89	6.55–9.58	9.85	7.12–13.63
61–80 y	7,625	6,944 (21.9%)	681 (33.0%)	7.18	5.96–8.71	7.51	5.38–10.49
81+ years	2,404	2,236 (7.1%)	168 (8.2%)	5.50	4.36–6.95	3.99	2.74–5.81
Race/Ethnicity[‡]							
Non-Hispanic White	14,135	13,038 (41.1%)	1,097 (53.2%)	1.00	Ref.		
Non-Hispanic Black	2,663	2,520 (8.0%)	143 (6.9%)	0.67	0.56–0.80		
Hispanic	11,931	11,351 (35.8%)	580 (28.1%)	0.61	0.55–0.67		
Asian/ Hawaiian/Pacific Islander	1,998	1,920 (6.10%)	78 (3.8%)	0.48	0.38–0.62		
Filipino	1,267	1,192 (3.8%)	75 (3.6%)	0.75	0.58–0.95		
American Indian or Alaska Native/Multiple/Other /Unknown (AI/AN/Other)	1,762	1,674 (5.3%)	88 (4.3%)	0.63	0.50–0.78		
Clinic Setting							
Emergency	5,029	4,743 (15.0%)	286 (13.9%)	1.00	Ref.	1.00	Ref.
Urgent care	4,918	4,349 (13.7%)	569 (27.6%)	2.17	1.87–2.52	1.27	1.06–1.54
Family or Internal medicine	12,619	11,717 (37.0%)	902 (43.8%)	1.28	1.12–1.47	1.29	1.09–1.52
Pediatrics	10,302	10,132 (32.0%)	170 (8.3%)	0.28	0.23–0.34	1.08	0.77–1.51
Pulmonary	165	116 (0.4%)	49 (2.4%)	7.01	4.88–9.93	6.02	3.95–9.17
Unknown or other clinics	723	638 (2.0%)	85 (4.1%)	2.21	1.70–2.84	0.78	0.56–1.07
County of Residence							
Los Angeles County	13,709	12,983 (41.0%)	726 (35.0%)	1.00	Ref.	1.00	Ref.
Kern County	1,454	815 (2.6%)	639 (31.0%)	14.02	12.34–15.93	18.43	15.64–21.72
Orange County	4,084	3,980 (12.6%)	104 (5.1%)	0.47	0.38–0.57	0.34	0.27–0.43
Riverside County	3,163	3,042 (9.6%)	121 (5.9%)	0.71	0.58–0.86	0.60	0.49–0.74
San Bernardino County	3,717	3,601 (11.4%)	116 (5.6%)	0.58	0.47–0.70	0.45	0.37–0.56
San Diego County	6,696	6,411 (20.2%)	285 (13.8%)	0.80	0.69–0.91	0.66	0.57–0.78
Ventura County	884	819 (2.6%)	65 (3.2%)	1.42	1.08–1.83	0.98	0.73–1.31
Other County**	49	44 (0.1%)	5 (0.2%)	2.03	0.70–4.68	1.22	0.43–3.48
History of DM	5,255	4,811 (15.2%)	444 (21.5%)	1.53	1.37–1.71	0.69	0.60–0.79
History of COPD	3,541	3,187 (10.1%)	354 (17.2%)	1.86	1.64–2.09	0.63	0.53–0.74
History of Asthma	10,196	9,640 (30.4%)	556 (27.0%)	0.85	0.76–0.93	0.82	0.73–0.93
History of Neoplasm or cancer	4,188	3,799 (12.0%)	389 (18.9%)	1.71	1.52–1.92	0.89	0.77–1.03
History of HIV/AIDS	89	71 (0.2%)	18 (0.9%)	3.92	2.27–6.44	3.39	1.86–6.16
History of Tuberculosis	150	136 (0.4%)	14 (0.7%)	1.59	0.87–2.66		
Prescribed chemotherapy agents within one week before/on CAP diagnosis	72	61 (0.2%)	11 (0.5%)	2.79	1.39–5.08	1.29	0.56–2.95
Prescribed corticosteroid agents within one week before/on CAP diagnosis	6,876	6,450 (20.4%)	426 (20.7%)	1.02	0.91–1.14		

Characteristic	Total CAP Patients	Patients Not-tested for Coccidioidomycosis* Total n = 31,695 (100%)	Patients Tested for Coccidioidomycosis* Total n = 2,061 (100%)	Odds Ratio	95% CI	Adjusted Odds Ratio*	95% CI
Influenza-like illness within 4 weeks before/on CAP diagnosis	3,825	3,614 (11.4%)	211 (10.2%)	0.89	0.76–1.02		
Pregnant during any time in 2011 (female CAP patient only) [‡]	103	97 (0.6%)	6 (0.6%)	1.00	0.39–2.11		
Died before January 1, 2013	1,374	1,140 (3.6%)	234 (11.4%)	3.43	2.95–3.98		
Total number of encounters (outpatient and emergency) within 4 weeks before CAP diagnosis							
0	15,898	15,113 (47.7%)	785 (38.1%)	1.00	Ref.	1.00	Ref.
1	9,705	9,123 (28.8%)	582 (28.2%)	1.23	1.10–1.37	1.16	1.02–1.32
2	4,413	4,095 (12.9%)	318 (15.4%)	1.50	1.31–1.71	1.22	1.04–1.43
3	1,865	1,706 (5.4%)	159 (7.7%)	1.79	1.50–2.14	1.21	0.98–1.50
4+	1,875	1,658 (5.2%)	217 (10.5%)	2.52	2.15–2.95	1.25	1.02–1.52
Total number of CAP follow up encounters within one year after CAP diagnosis							
0	21,544	20,946 (66.1%)	598 (29.0%)	1.00	Ref.	1.00	Ref.
1	7,212	6,706 (21.2%)	506 (24.6%)	2.64	2.34–2.98	2.05	1.66–2.52
2	2,635	2,313 (7.3%)	322 (15.6%)	4.88	4.23–5.62	3.17	2.46–4.11
3	1,142	912 (2.9%)	230 (11.2%)	8.83	7.47–10.41	5.72	4.24–7.72
4+	1,223	818 (2.6%)	405 (19.7%)	17.34	15.01–20.03	9.02	6.46–12.60
Follow up emergency services within one year after CAP diagnosis	2,102	1,703 (5.4%)	399 (19.4%)	4.23	3.75–4.76	0.75	0.61–0.92
Admitted to hospital (inpatient) within one year after CAP diagnosis	2,492	1,974 (6.2%)	518 (25.1%)	5.06	4.53–5.64	1.52	1.25–1.85
x-ray ordered within one year follow up visits after CAP diagnosis	9,673	8,382 (26.5%)	1,291 (62.6%)	4.66	4.25–5.12	1.34	1.10–1.62
Total number of times prescribed corticosteroid agents within one week before/on follow-up visits within one year after CAP diagnosis							
0	31,283	29,631 (93.5%)	1,652 (80.2%)	1.00	Ref.	1.00	Ref.
1	1,974	1,706 (5.4%)	268 (13.0%)	2.82	2.45–3.23	1.04	0.87–1.26
2	355	253 (0.8%)	102 (5.0%)	7.23	5.69–9.12	1.38	1.00–1.91
3	98	75 (0.2%)	23 (1.1%)	5.50	3.37–8.65	0.63	0.34–1.17
4+	46	30 (0.1%)	16 (0.8%)	9.57	5.08–17.34	0.95	0.42–2.14
Total number of times prescribed additional antibiotic agents within one week before/on follow-up visits within one year after CAP diagnosis [‡]							
0	29,248	27,865 (87.9%)	1,383 (67.1%)	1.00	Ref.	1.00	Ref.
1	3,607	3,152 (9.9%)	455 (22.1%)	2.91	2.60–3.25	1.36	1.15–1.60
2	669	523 (1.7%)	146 (7.1%)	5.63	4.63–6.79	1.62	1.23–2.14
3	161	108 (0.3%)	53 (2.6%)	9.89	7.04–13.72	2.10	1.31–3.35
4+	71	47 (0.2%)	24 (1.2%)	10.29	6.18–16.70	2.02	1.04–3.83
Race/Ethnicity * Death							
Non-Hispanic White + Death (N)						1.00	Ref.
Non-Hispanic White + Death (Y)						1.79	1.40–2.27
Non-Hispanic Black + Death (Y)						0.89	0.41–1.94
Hispanic + Death (Y)						1.91	1.30–2.81
Asian/ Hawaiian/Pacific Islander + Death (Y)						0.89	0.31–2.60

Characteristic	Total CAP Patients	Patients Not-tested for Coccidioidomycosis* Total n = 31,695 (100%)	Patients Tested for Coccidioidomycosis* Total n = 2,061 (100%)	Odds Ratio	95% CI	Adjusted Odds Ratio*	95% CI
Filipino + Death (Y)						7.79	3.60–16.85
AI/AN/Other + Death (Y)						3.12	1.30–7.54
Non-Hispanic Black + Death (N)						0.86	0.69–1.07
Hispanic + Death (N)						0.81	0.71–0.93
Asian/ Hawaiian/Pacific Islander + Death (N)						0.95	0.73–1.24
Filipino + Death (N)						0.89	0.66–1.20
AI/AN/Other + Death (N)						0.86	0.65–1.12

£Put back into the final model although it was eliminated by the model backward selection algorithm

‡Not included in the multivariable analysis because it only applied to females

*Tested within 1 y after CAP diagnosis

**Other County includes: Alameda County, Anderson County, Burlington County, Butte County, Carver County, Clark County, Clearwater County, Contra Costa County, Fresno County, Imperial County, Kauai County, Kootenai County, La Paz County, Merced County, Mohave County, Sacramento County, Santa Barbara County, Santa Clara County, Shasta County, Tulare County

‡All patients received at least one course of antibiotics; prescription of a systemic antibiotic from 2 weeks before to 4 weeks after the index date was one component of the CAP patient definition

‡Gray colored cells indicate variables that were not included in adjusted analyses due to P-value >0.2 in unadjusted analyses, or were not considered confounders a priori

Technical Appendix Table 3. Enzyme Immunoassay Testing for Coccidioidomycosis among Community-Acquired Pneumonia Patients Presenting in 2011, by Confirmatory Complement Fixation or Immunodiffusion Test

Enzyme Immunoassay (EIA)	Complement Fixation or Immunodiffusion*			
	Positive, no. (%)	Negative, no. (%)	Tested, unknown, no. (%)	Not tested, no. (%)
Positive by IgG + IgM (n = 170)	149 (87.65)	19 (11.18)	0 (0.00)	2 (1.18)
Positive by IgG Only (n = 71)	7 (9.86)	61 (85.92)	1 (1.41)	2 (2.82)
Positive by IgM Only (n = 129)	9 (6.98)	118 (91.47)	0 (0.00)	2 (1.55)
No EIA (n = 7)	7 (100.00)	0 (0.00)	0 (0.00)	0 (0.00)
Total (n = 377)	172 (45.62)**	198 (52.52)	1 (0.27)	6 (1.59)

*Tests performed within one year following a positive IgG and/or IgM test

**Of the 172 patients with confirmatory testing by complement fixation and/or immunodiffusion, 17 also had a positive culture or histopathology for Coccidioides.

Technical Appendix Table 4. Comparison of Characteristics of Patients with Confirmed Coccidioidomycosis versus those Testing Negative among Community-Acquired Pneumonia (CAP) Patients Presenting in 2011 who were Tested for Coccidioidomycosis

Characteristic	Total Patients Tested for Coccidioidomycosis	Patients Tested for Coccidioidomycosis with Negative Test Total n = 1889 (100%)	Patients with Confirmed Coccidioidomycosis ^a Total n = 172 (100%)	Odds Ratio	95% CI	Adjusted Odds Ratio [*]	95% CI
Sex^E							
Female	992	932 (49.3%)	60 (34.9%)	0.55	0.40–0.76	0.60	0.42–0.86
Male	1,069	957 (50.7%)	112 (65.1%)	1.00	Ref.	1.00	Ref.
Age Group							
≤9 y	130	125 (6.6%)	5 (2.9%)	1.00	Ref.	1.00	Ref.
10–18 y	103	87 (4.6%)	16 (9.3%)	4.60	1.62–13.0	6.71	2.28–19.70
19–40 y	279	231 (12.2%)	48 (27.9%)	5.20	2.02–13.38	9.96	2.64–37.54
41–60 y	700	629 (33.3%)	71 (41.3%)	2.82	1.12–7.13	8.38	2.25–31.25
61–80 y	681	651 (34.5%)	30 (17.4%)	1.15	0.49–3.03	5.95	1.52–23.33
81+ years	168	166 (8.8%)	2 (1.2%)	0.30	0.06–1.58	2.31	0.33–16.39
Race/Ethnicity							
Non-Hispanic White	1,097	1038 (55.0%)	59 (34.3%)	1.00	Ref.	1.00	Ref.
Non-Hispanic Black	143	124 (6.6%)	19 (11.1%)	2.70	1.56–4.67	2.78	1.50–5.12
Hispanic	580	509 (27.0%)	71 (41.3%)	2.45	1.71–3.52	1.83	1.23–2.73
Asian/ Hawaiian/Pacific Islander	78	70 (3.7%)	8 (4.7%)	2.01	0.92–4.37	1.78	0.77–4.12
Filipino	75	65 (3.4%)	10 (5.8%)	2.71	1.32–5.54	3.56	1.57–8.08
American Indian or Alaska Native/ Multiple /Other /Unknown	88	83 (4.4%)	5 (2.9%)	1.06	0.41–2.71	0.85	0.32–2.29
Clinic Setting							
Emergency	286	278 (14.7%)	8 (4.7%)	1.00	Ref.	1.00	Ref.
Urgent care	569	502 (26.6%)	67 (39.0%)	4.64	2.20–9.80	1.87	0.81–4.32
Family and Internal medicine	902	837 (44.3%)	65 (37.8%)	2.70	1.28–5.70	1.50	0.67 - 3.40
Pediatrics	170	154 (8.2%)	16 (9.3%)	3.61	1.51–8.63	2.61	0.68–9.99
Pulmonary	49	48 (2.5%)	1 (0.6%)	0.72	0.09–5.92	0.79	0.09–6.92
Unknown or other clinics	85	70 (3.7%)	15 (8.7%)	7.45	3.04–18.26	4.04	1.46–11.20
County of Residence							
Los Angeles County	726	685 (36.3%)	41 (23.8%)	1.00	Ref.	1.00	Ref.
Kern County	639	541 (28.6%)	98 (57.0%)	3.03	2.07–4.43	2.48	1.56–3.95
Orange County	104	100 (5.3%)	4 (2.3%)	0.67	0.23–1.91	0.77	0.25–2.34
Riverside County	121	109 (5.8%)	12 (7.0%)	1.84	0.94–3.61	1.98	0.95–4.14
San Bernardino County	116	112 (5.9%)	4 (2.3%)	0.60	0.21–1.70	0.62	0.21–1.84
San Diego County	285	275 (14.6%)	10 (5.8%)	0.61	0.30–1.23	0.78	0.36–1.69
Ventura County	65	62 (3.3%)	3 (1.7%)	0.81	0.24–2.69	0.83	0.22–3.08
Other County**	5	5 (0.3%)	0 (0.0%)				
History of DM	444	427 (22.6%)	17 (9.9%)	0.38	0.23–0.63	0.41	0.23–0.73
History of COPD	354	348 (18.4%)	6 (3.5%)	0.16	0.07–0.36	0.37	0.15–0.91
History of Asthma	556	529 (28.0%)	27 (15.7%)	0.48	0.31–0.73	0.68	0.42–1.09
History of Neoplasm or cancer	389	372 (19.7%)	17 (9.9%)	0.45	0.27–0.75	1.13	0.63–2.03
History of HIV/AIDS	18	17 (0.9%)	1 (0.6%)	0.65	0.09–4.87	0.72	0.08–6.28
History of Tuberculosis	14	13 (0.7%)	1 (0.6%)	0.84	0.11–6.49		
Prescribed chemotherapy agents within one week before/on CAP diagnosis	11	10 (0.5%)	1 (0.6%)	1.10	0.14–8.64		
Prescribed corticosteroid agents within one week before/on CAP diagnosis	426	393 (20.8%)	33 (19.2%)	0.90	0.61–1.34		

Characteristic	Total Patients Tested for Coccidioidomycosis	Patients Tested for Coccidioidomycosis with Negative Test Total n = 1889 (100%)	Patients with Confirmed Coccidioidomycosis ^a Total n = 172 (100%)	Odds Ratio	95% CI	Adjusted Odds Ratio [†]	95% CI
Influenza-like illness within 4 weeks before/on CAP diagnosis	211	189 (10.0%)	22 (12.8%)	1.32	0.82–2.12	1.12	0.67–1.88
Pregnant during any time in 2011 (female CAP patient only) [‡]	6	6 (0.6%)	0 (0.0%)				
Died before January 1, 2013	234	231 (12.2%)	3 (1.7%)	0.13	0.04–0.40	0.34	0.10–1.16
Total Number of encounters (outpatient and emergency) within 4 weeks before CAP diagnosis							
0	785	709 (37.5%)	76 (44.2%)	1.00	Ref.		
1	582	530 (28.1%)	52 (30.2%)	0.92	0.63–1.33		
2	318	291 (15.4%)	27 (15.7%)	0.87	0.55–1.37		
3	159	153 (8.1%)	6 (3.5%)	0.37	0.16–0.86		
4+	217	206 (10.0%)	11 (6.4%)	0.50	0.26–0.96		
Total Number of CAP follow-up encounters within one year after CAP diagnosis							
0	598	564 (29.9%)	34 (19.8%)	1.00	Ref.		
1	506	454 (24.0%)	52 (30.2%)	1.90	1.21–2.98		
2	322	290 (15.4%)	32 (18.6%)	1.83	1.11–3.03		
3	230	207 (11.0%)	23 (13.4%)	1.84	1.06–3.20		
4+	405	374 (19.8%)	31 (18.0%)	1.38	0.83–2.28		
Follow up emergency department visits within one year after CAP diagnosis	399	379 (20.1%)	20 (11.6%)	0.52	0.33–0.85	1.17	0.62–2.19
Inpatient stays within one year after CAP diagnosis	518	502 (26.6%)	16 (9.3%)	0.28	0.17–0.48	0.41	0.21–0.80
x-ray ordered within one year follow-up visits after CAP diagnosis	1,291	1,162 (61.5%)	129 (75.0%)	1.88	1.31–2.68	2.30	1.54–3.45
Total number of times prescribed corticosteroid agents during CAP visits from one week before/on initial CAP visit through first coccidioidomycosis test							
0	1,890	1,722 (91.2%)	168 (97.7%)	1.00	Ref.	1.00	Ref.
1+	171	167 (8.8%)	4 (2.3%)	0.25	0.09–0.67	0.29	0.09–0.94
Total number of times prescribed additional antibiotic agents during CAP visits from one week before/on initial CAP visit through first coccidioidomycosis test [‡]							
0	1,746	1,596 (84.5%)	150 (87.2%)	1.00	Ref.	1.00	Ref.
1	262	244 (12.9%)	18 (10.5%)	0.79	0.47–1.30	1.46	0.77–2.77
2+	53	49 (2.6%)	4 (2.3%)	0.87	0.46–3.68	4.57	1.29–16.12
Total number of encounters between initial CAP diagnosis and first coccidioidomycosis test							
0	659	588 (31.1%)	71 (41.3%)	1.00	Ref.	1.00	Ref.
1	324	293 (15.5%)	31 (18.0%)	0.88	0.56–1.37	1.39	0.82–2.33
2	243	219 (11.6%)	24 (14.0%)	0.91	0.56–1.48	1.49	0.84–2.64
3	172	160 (8.5%)	12 (7.0%)	0.62	0.33–1.17	1.09	0.53–2.27

Characteristic	Total Patients Tested for Coccidioidomycosis	Patients Tested for Coccidioidomycosis with Negative Test Total n = 1889 (100%)	Patients with Confirmed Coccidioidomycosis ^a Total n = 172 (100%)	Odds Ratio	95% CI	Adjusted Odds Ratio [†]	95% CI
4+	663	629 (33.3%)	34 (19.8%)	0.45	0.29–0.68	0.95	0.54–1.65
Total days after initial CAP diagnosis that first coccidioidomycosis lab test was ordered [§]							
Mean (SD)	46.3 (84.4)	48.7 (86.5)	19.8 (48.7)				
Median (Range)	6 (0–365)	6.0 (0–365)	4 (0–287)				

^aConfirmed by immunodiffusion and/or complement fixation test. Does not include the 3 patients identified by histopathology or culture

£Maintained in final model despite elimination by backward selection

‡Not included in the multivariate analysis; only applies to females

§ Tested by Wilcoxon rank sum test

*Tested within 1 y after CAP diagnosis

**Other County includes: Alameda County, Anderson County, Burlington County, Butte County, Carver County, Clark County, Clearwater County, Contra Costa County, Fresno County, Imperial County, Kauai County, Kootenai County, La Paz County, Merced County, Mohave County, Sacramento County, Santa Barbara County, Santa Clara County, Shasta County, Tulare County

¢All patients received at least one course of antibiotics; prescription of a systemic antibiotic from 2 weeks before to 4 weeks after the index date was one component of the CAP patient definition

¥Gray colored cells indicate variables that were not included in adjusted analyses due to P-value >0.2 in unadjusted analyses, or were not considered confounders a priori.